QIAGEN provides reminder on settlement mechanics of 2023 and 2024 convertible notes
16 Juni 2023 - 1:36PM
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced
today a notice (reiterating its notice to holders dated January 9,
2019) to holders of the following:
- 0.500% Senior Unsecured Convertible Notes due 2023 (the
"2023 Notes") – ISIN XS1682511818- 1.000% Senior Unsecured
Convertible Notes due 2024 (the "2024 Notes") – ISIN
XS1908221507Collectively, the “Notes”
This reminder has been issued following
consultation with the Calculation Agent. (Capitalized terms not
otherwise defined in this notice shall have the meaning given to
them in the respective Indentures of the Notes.)
When determining the Daily VWAP in respect of
any of the 2023 Notes for so long as the Relevant Exchange is the
New York Stock Exchange (NYSE), or until and unless the Calculation
Agent determines otherwise in its sole discretion (in accordance
with the definition of “Daily VWAP”), the Calculation Agent will
observe the Daily VWAP on the Bloomberg page “QGEN US
<equity> AQR”, using “09:30:00” (Local Time) as the start
time input for the scheduled opening of trading and “16:00:00”
(Local Time) as the end time.
For the avoidance of doubt, (i) the Calculation
Agent will also use these settings, in accordance with the
Indenture, for the 2024 Notes, and (ii) the use of these time
settings would normally be expected to result in the inclusion of
the trades which occur in the opening auction, and the exclusion of
trades which occur in the closing auction of the Common Stock on
the New York Stock Exchange, consistent with the fact that the
NASDAQ opening cross would have been included and the NASDAQ
closing cross would have been excluded, had the same time settings
been used (pursuant to the definition of “Daily VWAP”) whilst the
Relevant Exchange was the NASDAQ Global Select Market (having been
the Relevant Exchange at the date of issuance of the 2023
Notes.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
March 31, 2023, QIAGEN employed more than 6,200 people in over
35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024